PAT-048 |
Catalog No.GC36859 |
PAT-048 est un inhibiteur d'autotaxine puissant, sélectif et actif par voie orale, inhibe l'expression de l'ARNm de l'IL-6, mais ne montre aucun effet sur la production de protéine d'autotaxine et d'acide lysophosphatidique pulmonaire (LPA) dans le modèle de fibrose pulmonaire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1359983-15-5
Sample solution is provided at 25 µL, 10mM.
PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo[1][2]. IC50: 20 nM (Autotaxin, in mouse plasma)[1] IC90: 200 nM (Autotaxin, in mouse plasma)[1]
[1]. Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. [2]. Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30(6):2435-50.
Average Rating: 5
(Based on Reviews and 21 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *